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Pokushalov and colleagues reported the first-in-man randomized clinical trial (NCT01117025) 
comparing the effects of pulmonary vein isolation with (intervention) or without (control) renal 
denervation in patients with refractory atrial fibrillation and treatment-resistant hypertension (1).  
We were struck by several inconsistences in this trial.   
First, of particular concern are the changes in design, primary endpoint, sample size, and inclu-
sion and exclusion criteria from the successive protocols posted at http://www.clinicaltrials.gov 
(see Supplementary Material available online) to the published report (1).  The original protocol 
identified office systolic blood pressure at 2 years – not recurrence of atrial fibrillation at 1 year – 
as the primary endpoint that should have informed the sample size calculations.  The number of 
patients actually randomized was 27 (1), one more than required according to last version of the 
protocol at the registry website, and 82% less than first planned for (n=150).  The discrepancy is 
especially worrisome, because the P-value for the between-group difference in the incidence of 
atrial arrhythmia was only 0.033 (1), so that adding a single control patient (14 instead of 13) 
might have made the statistical significance.  The results of atrial ablation in the control group 
were dismal (2).  Previous use of amiodarone was an exclusion criterion in the published paper 
(1), but not in any version of the design in the trial registry.  The original exclusion criterion of 
secondary atrial hypertension was changed into secondary hypertension without mention of the 
diagnostic procedures.  At variance with the CONSORT statement (3), the number of patient 
screened and invited remains unreported (1).   
Second, Pokushalov’s trial was registered as investigator driven without industry sponsor.  Re-
searchers were originally located in Novosibirsk and Athens.  An employee from industry coau-
thored the published report (1).  The group, who first published on the blanking period (4) and 
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also received industry support (1), was also added at the publication stage.  Pokushalov excluded 
the first 3 months after pulmonary vein isolation from the analysis of recurrent atrial fibrillation 
(1).  This so-called blanking period (4) should not have been longer than 2 to 4 weeks, because 
recurrence of atrial fibrillation significantly declines after 1 month and thereafter remains stable 
(5).  Moreover, all of Pokushalov’s patients were treated with propafenone or flecainide for 6 
weeks after the procedure (1).   
Third, the published methods (1) are not detailed enough to allow an independent replication of 
the study.  The catheter used to stimulate the renal nerves is not mentioned.  An exhaustive inter-
net search for the Stimulator B-53 led us to http://www.biotok.ru.  This company is currently 
located in Tomsk, not in Saint Petersburg.  We could not access their website, because of an 
HTTP 500 Internal Server Error.  Furthermore, Pokushalov’s paper does not provide any infor-
mation on the technique or reproducibility of the echocardiographic measurements (1).   
Fourth, there are possible differences between described and applied statistical methods.  The 
authors stated that continuous variables were presented as mean±SD and analyzed by t test (1).  
Systolic/diastolic blood pressure averaged 178±8/96±4 mm Hg in 14 control patients and 
181±7/97±6 mm Hg in 13 patients of the intervention group.  For the blood pressure level, SDs 
around 8 mm Hg systolic and 5 mm Hg diastolic seem unrealistic, unless patients were selected 
within narrow blood pressure limits.  Reportedly, in the interventional group, the fall in blood 
pressure at 12 month averaged -25±5 mm Hg systolic and -10±2 mm Hg diastolic (1), while the 
change read from Figure 5 (1) was -25±3 mm Hg systolic.  Recalculation of the P-values, using 
an unpaired t test and the blood pressure changes digitized from Figure 5, showed that the meas-
ure of spread for both blood pressure and blood pressure fall was probably not SD, but more 
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likely SE.  For comparison, in the SYMPLICITY HTN-2 study (6), office blood pressure (±SD) 
averaged 178±16/98±17 mm Hg in the control group (n=52) and 178±18/97±16 mm Hg in the 
renal denervation group (n=52), and the blood pressure changes at 6 months (±SD) were 
1±21/0±10 mm Hg in the control group and - 32±23/12±11 mm Hg in the denervation group.  
SD is not dependent on sample size, whereas SE is.   
Fifth, Pokushalov and colleagues (1) did not report key test statistics and rounded measures of 
central tendency and spread to a single meaningful digit.  In a parallel-group trial, P-values for 
the within-group changes in an outcome variable provide some information, but the main test 
statistics should rest on baseline-adjusted between-group differences in the endpoint.  Poku-
shalov did not show these key statistical parameters (1).  Furthermore, the echocardiographic 
results were not consistently reported throughout paper.  Table 1 shows baseline values only for 
left atrial diameter and left ventricular ejection fraction (1).  Next, Table 2 gives changes from 
baseline in thickness of the interventricular septum, posterior wall, left ventricular internal di-
ameter and left ventricular mass index, of which baseline values were not given (1).  Moreover, 
echocardiographic measurements were expressed in unusual units: centimeter instead of millime-
ter for the interventricular septum, the posterior wall and the left ventricular internal diameter, 
and g/m, not g/m2, for left ventricular mass index.  This issue is not trivial, as the changes in left 
ventricular walls and internal diameter were small with average within-group changes ranging 
from 0.1 to 1 millimeter.  Rounding measures of central tendency and spread to a single mean-
ingful decimal and reporting left ventricular echocardiographic measurements in centimeters 
rather than millimeters makes it difficult to reproduce P-values from the published data.   
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Sixth, one other potential inaccuracy pertains to the number of drugs taken.  According to Table 
1 (1),  the number of antiarrhythmic drugs averaged 3.6 (range, 2 to 5) in control patients and 3.8 
(range, 2 to 5) in the intervention group.  The number of antihypertensive drugs was the same, 
albeit with different ranges as reported in the Results: 3.6 (range, 3 to 5) and 3.8 (range, 3 to 5), 
respectively.  The use of 5 antiarrhythmic drug in a single patient, is incompatible with current 
guidelines (7).   
According to Ioannidis’ seminal essay (8), several corollaries for a possible false result might 
apply to Pokushalov’s study (1).  The likelihood that research findings are true decreases with 
smaller sample size (corollary 1); greater flexibility in designs, definitions, outcomes, and ana-
lytical methods (corollary 4); greater financial or other interests and preconceived ideas in a 
scientific field (corollary 5); and hotter research topics (corollary 6).  In conclusion, the methodo-
logical drawbacks in Pokushalov’s report (1) cast doubt on its validity, which clearly does not 
comply with CONSORT standards (3).  Our observations highlight the necessity to have the 
design, methods, statistics and conclusions of Pokushalov’s report revised (1) and to continue 
remaining vigilant about the peer-review process.   
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